SURAKSHA

Suraksha Diagnostic Share Price

 

Stock Result Declared

 

Start SIP in SURAKSHA

Start SIP

Performance

  • Low
  • ₹309
  • High
  • ₹316
  • 52 Week Low
  • ₹231
  • 52 Week High
  • ₹449
  • Open Price₹315
  • Previous Close₹323
  • Volume68,082

Investment Returns

  • Over 1 Month + 7.61%
  • Over 3 Month + 5.23%
  • Over 6 Month + 10.82%
  • Over 1 Year -28.83%

Smart Investing Starts Here Start SIP with Suraksha Diagnostic for Steady Growth!

Invest Now

Suraksha Diagnostic Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.2
  • PEG Ratio
  • 6.6
  • Market Cap Cr
  • 1,635
  • P/B Ratio
  • 8.2
  • Average True Range
  • 9.36
  • EPS
  • 6.39
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.06
  • RSI
  • 50.9
  • MFI
  • 76

Suraksha Diagnostic Financials

Suraksha Diagnostic Technicals

EMA & SMA

Current Price
₹313.85
-9.2 (-2.85%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹314.64
  • 50 Day
  • ₹310.72
  • 100 Day
  • ₹311.79
  • 200 Day
  • ₹316.27

Resistance and Support

312.88 Pivot Speed
  • R3 323.42
  • R2 319.58
  • R1 316.72
  • S1 310.02
  • S2 306.18
  • S3 303.32

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suraksha Diagnostic Limited provides diagnostic and healthcare services with over 100 centers across India. It offers pathology, radiology, and imaging services, catering to diverse healthcare needs. The company emphasizes accuracy, affordability, and accessibility in delivering diagnostic solutions.

Suraksha Diagnostic Limited has an operating revenue of Rs. 263.95 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 16% is great, ROE of 15% is good. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 3% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Services and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Suraksha Diagnostic Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-08-08 Quarterly Results
2025-05-28 Audited Results & Final Dividend
2025-02-08 Quarterly Results
2024-12-20 Quarterly Results

Suraksha Diagnostic F&O

Suraksha Diagnostic Shareholding Pattern

48.98%
19.45%
0%
0.85%
0%
12.95%
17.77%

About Suraksha Diagnostic

  • NSE Symbol
  • SURAKSHA
  • BSE Symbol
  • 544293
  • Joint Managing Director & CEO
  • Ms. Ritu Mittal
  • ISIN
  • INE877V01027

Similar Stocks to Suraksha Diagnostic

Suraksha Diagnostic FAQs

Suraksha Diagnostic share price is ₹313 As on 11 November, 2025 | 22:30

The Market Cap of Suraksha Diagnostic is ₹1634.6 Cr As on 11 November, 2025 | 22:30

The P/E ratio of Suraksha Diagnostic is 51.2 As on 11 November, 2025 | 22:30

The PB ratio of Suraksha Diagnostic is 8.2 As on 11 November, 2025 | 22:30

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23